- Home
- / Adimmune Corporation
Adimmune Corporation
Stock Price
NT$24.3
2024-10-29
Market Capitalization
NT$10.2 B
2024-10-29
Revenue
NT$1.6 B
FY, 2024
Adimmune Corporation Summary
Company Summary
- Overview
- Adimmune Corporation (ADIM, 國光生物科技股份有限公司) is an influenza vaccine manufacturer. It offers Japanese Encephalitis Vaccine produced using a mouse brain. The company also develops AdimFlu-S and Tetanus Toxoid Alum Precipitated, a sterilized suspension obtained after virus attenuation by formaldehyde treatment and adsorption with aluminum phosphate.
- Type
- Public
- Status
- Active
- Founded
- 1965
- HQ
- TW | view all locations
- Website
- http://www.adimmune.com.tw/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Chi-Hsien Chan, Chairman & CEO
Peter Pan, General Counsel
Nathan Chen, Chief Medical Officer
LocationsView all
3 locations detected
Taichung City HQ
Taiwan
No. 3號, Section 1, Tanxing Road, Tanzi District
Taipei City
Taiwan
Taichung City
Taiwan
No. 389, Section 2, Xiangshun Rd, Beitun District
Adimmune Corporation Financials
Summary Financials
- Revenue (Q3, 2025)
- NT$475.3M
- Gross profit (Q3, 2025)
- NT$259.5M
- Net income (Q3, 2025)
- (NT$38.6M)
- Cash (Q3, 2025)
- NT$1.8B
- EBIT (Q3, 2025)
- (NT$52.4M)
- Enterprise value
- $11.7B